256 related articles for article (PubMed ID: 18981012)
1. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP; Arkenau HT; Harrington K; Roxburgh P; Morrison R; Roulstone V; Twigger K; Coffey M; Mettinger K; Gill G; Evans TR; de Bono JS
Clin Cancer Res; 2011 Feb; 17(3):581-8. PubMed ID: 21106728
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
Laurie SA; Bell JC; Atkins HL; Roach J; Bamat MK; O'Neil JD; Roberts MS; Groene WS; Lorence RM
Clin Cancer Res; 2006 Apr; 12(8):2555-62. PubMed ID: 16638865
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Nokisalmi P; Pesonen S; Escutenaire S; Särkioja M; Raki M; Cerullo V; Laasonen L; Alemany R; Rojas J; Cascallo M; Guse K; Rajecki M; Kangasniemi L; Haavisto E; Karioja-Kallio A; Hannuksela P; Oksanen M; Kanerva A; Joensuu T; Ahtiainen L; Hemminki A
Clin Cancer Res; 2010 Jun; 16(11):3035-43. PubMed ID: 20501623
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
9. An optimized clinical regimen for the oncolytic virus PV701.
Hotte SJ; Lorence RM; Hirte HW; Polawski SR; Bamat MK; O'Neil JD; Roberts MS; Groene WS; Major PP
Clin Cancer Res; 2007 Feb; 13(3):977-85. PubMed ID: 17289893
[TBL] [Abstract][Full Text] [Related]
10. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ; Karapanagiotou EM; Roulstone V; Twigger KR; White CL; Vidal L; Beirne D; Prestwich R; Newbold K; Ahmed M; Thway K; Nutting CM; Coffey M; Harris D; Vile RG; Pandha HS; Debono JS; Melcher AA
Clin Cancer Res; 2010 Jun; 16(11):3067-77. PubMed ID: 20484020
[TBL] [Abstract][Full Text] [Related]
11. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
13. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
14. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
16. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.
Freeman AI; Zakay-Rones Z; Gomori JM; Linetsky E; Rasooly L; Greenbaum E; Rozenman-Yair S; Panet A; Libson E; Irving CS; Galun E; Siegal T
Mol Ther; 2006 Jan; 13(1):221-8. PubMed ID: 16257582
[TBL] [Abstract][Full Text] [Related]
18. Reovirus-based therapy for cancer.
Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
[TBL] [Abstract][Full Text] [Related]
19. Modification of mammalian reoviruses for use as oncolytic agents.
Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
[TBL] [Abstract][Full Text] [Related]
20. Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses.
Rajecki M; Raki M; Escutenaire S; Pesonen S; Cerullo V; Helminen A; Hannuksela P; Partanen K; Laasonen L; Joensuu T; Kangasniemi L; Haavisto E; Kanerva A; Ahtiainen L; Hemminki A
Mol Pharm; 2011 Feb; 8(1):93-103. PubMed ID: 20964369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
